Trial | NCT01115426  Report issue

Title

Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis
Long-term Treatment by Inhibitors of Angiotensin II at Low Doses in Non-nephrotic Proteinuric Patients With Pauciimmune and IgA Mesangioproliferative Glomerulonephritis

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    20
This study evaluates prospectively the effects of an anti-angiotensin II regimen on renal outcome in patients with mesangioproliferative glomerulonephritis followed-up for 10 years.
After signing informed consent, enrolled patients started treatment with ACEi. We decided to prescribe to all patients the same drug (ramipril) at the same dosage (5 mg/day). All patients were examined every 2 months during the first year of follow-up and every 6 months thereafter. At each visit, they underwent a complete physical examination. If the target blood pressure of <140/90 mmHg was not achieved with ramipril monotherapy, addition of other antihypertensive drug(s) was allowed. Patients complaining adverse side effects attributed to ramipril were switched to losartan (50 mg/day). The patients were also prescribed a normal protein (1 gram/kg/day) and moderately salt-restricted (6-8 grams/day) diet throughout the study.
Study Started
Jan 31
1997
Primary Completion
Jan 31
2007
Study Completion
Jan 31
2008
Last Update
May 04
2010
Estimate

Drug Ramipril or losartan

Ramipril (5 mg/day) was started soon after the enrollment and continued throughout the follow-up, having Losartan (50 mg/day) as alternative.

  • Other names: renin-angiotensin system (RAS) inhibitors

anti-angiotensin II drugs Other

Never treated patients with non-nephrotic proteinuria (1-3 g/day), microhematuria, no-evidence of renal failure or other relevant diseases and with diagnosis of I-II stage IgA- or pauciimmune-MsPGN were considered eligible.

Criteria 

Inclusion Criteria:

proteinuria ≥ 1 g and < 3 g/24 hours stable during the 3 months of run-in
microscopic hematuria (with at least 10 red blood cells per high-power field), without other signs or symptoms of systemic diseases stable during the 3 months of run-in
no-evidence of renal failure or other relevant diseases
biopsy diagnosis of I-II stage IgA- or pauciimmune-MsPGN

Exclusion Criteria:

estimated Glomerular Filtration Rate (eGFR) <80 ml/min/1.73m2
previous immunosuppressive treatment
blood pressure (BP) >150/90 mmHg
No Results Posted